Matthew Taylor, an analyst from Jefferies, has initiated a new Buy rating on Shoulder Innovations, Inc. (SI).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Matthew Taylor has given his Buy rating due to a combination of factors that highlight Shoulder Innovations, Inc.’s (SI) strong position in the growing shoulder market. SI is gaining market share thanks to its superior clinical data and innovative implants, which are supported by advanced surgical planning tools. These advantages allow SI to outperform competitors and position itself as a leader in the industry. Taylor anticipates a compound annual growth rate (CAGR) of over 30% through 2028, as SI continues to capture market share from existing players.
Furthermore, Taylor’s price target of $19 is based on a valuation of approximately five times the estimated sales for 2026, which is slightly higher than the average for similar high-growth medical technology companies. This premium is justified by SI’s expected higher growth rates and margins, with gross margins projected to increase to 77.5% by 2028. The company’s implants have demonstrated long-term effectiveness with minimal adverse events, and its innovative ProVoyance system enhances surgical planning efficiency. These factors, combined with a robust patent portfolio and potential for product line expansion, underpin Taylor’s optimistic outlook on SI’s future growth prospects.
According to TipRanks, Taylor is a 5-star analyst with an average return of 7.9% and a 58.51% success rate. Taylor covers the Healthcare sector, focusing on stocks such as Boston Scientific, LivaNova, and Establishment Labs Holdings.
In another report released today, Piper Sandler also initiated coverage with a Buy rating on the stock with a $18.00 price target.